Neuropathic pain is a significant problem with few effective treatments lacking adverse
effects. The sigma-1 receptor (S1R) is a potential therapeutic target for neuropathic pain, as …

Sigma receptors modulate nociception, offering a potential therapeutic target to treat pain,
but relatively little is known regarding the role of sigma-2 receptors (S2R) in nociception. The …

Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception without
the liabilities of opioids, offering a promising therapeutic target to treat pain. The purpose of …

Neuropathic pain (NP) is a chronic condition resulting from damaged pain-signaling
pathways. It is a debilitating disorder that affects up to 10% of the world's population …

Pain has become an active clinical challenge due its etiological heterogeneity, symptoms
and mechanisms of action. In the search for new pharmacological therapeutic alternatives …

The discovery and synthesis of a new series of pyrimidines as potent sigma-1 receptor (σ1R)
antagonists, associated with pharmacological antineuropathic pain activity, are the focus of …

We designed and synthesized a novel series of piperidine propionamide derivatives as
potent sigma-1 (σ 1) receptor antagonists and mu (μ) opioid receptor agonists, and …

Sigma-1 receptors (S1Rs) are strongly correlated to neuropathic pain (NP), since their
inactivation may decrease allodynia or dysesthesia, promoting analgesic effects. In the …

Introduction Interest in sigma-1 receptors (S1Rs) has significantly increased in the last 25
years and more recently for their role in pain modulation. S1Rs are novel chaperone …

The sigma-2 receptor has been cloned and identified as Tmem97, which is a
transmembrane protein involved in intracellular Ca 2+ regulation and cholesterol …